CONTEXT: @entity7031 ( @entity7031 ) is associated with the mutation in the @entity27529 gene, which codes @entity27529 ( @entity27529 ), a @entity563 protease inhibitor. As a result of aging coupled with @entity3230 , clinical symptoms may vary. METHODS: The @entity1 was presented to our clinic with sparse and brittle hair along with @entity11782 , erythematous and scaling cutaneous lesions. The @entity1 underwent a clinical examination and laboratory analyzes. Based on the clinical and laboratory findings, the @entity1 was diagnosed with @entity7031 . Moreover, @entity1851 , Complement-3 (C3), C4 @entity3646 , @entity225 , @entity1356 and @entity4155 levels of serum were investigated as an apoptotic marker and a negative marker for @entity32 . RESULTS: Having undergone omalizumab treatment and a short-term (4 months) later, he had a decreased IgE, Ig G, prolactin, @entity1851 , @entity3646 , @entity225 , @entity1356 and @entity4155 levels. The IgA, IgM and @entity4417 , C4 levels were insignificant between before and after Omalizumab treatment. CONCLUSION: To the best of our knowledge, this is the first time that an association between omalizumab and @entity7031 was documented. In conclusion allergic skin symptoms ( @entity111 , @entity5105 ) and mucosal symptoms decreased in the @entity1 .

A case of XXXX : successful treatment with omalizumab and pulse prednisolone and its effects on cytokines and immunoglobulin levels.

@entity1 :: ('9606', 'Species') :: ['patient'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity11782 :: ('MESH:C535817', 'Disease') :: ['pruritic'] @entity225 :: ('3567', 'Gene') :: ['IL-5'] @entity1356 :: ('3553', 'Gene') :: ['IL-1b'] @entity4417 :: ('718', 'Gene') :: ['C3'] @entity27529 :: ('11005', 'Gene') :: ['lymphoepithelial Kazaltype related inhibitor', 'SPINK5', 'LEKTI'] @entity111 :: ('MESH:D011537', 'Disease') :: ['pruritus'] @entity7031 :: ('MESH:D056770', 'Disease') :: ['NS', 'Netherton syndrome'] @entity4155 :: ('3605', 'Gene') :: ['IL-17A'] @entity5105 :: ('MESH:D004890', 'Disease') :: ['erythema and desquamation'] @entity563 :: ('CHEBI:17822', 'Chemical') :: ['serine'] @entity3646 :: ('3565', 'Gene') :: ['IL-4'] @entity3230 :: ('MESH:C565469', 'Disease') :: ['immune deficiency'] @entity1851 :: ('1401', 'Gene') :: ['CRP']
@entity7031 :: (MESH:D056770,Disease) :: ['netherton syndrome']
